BioSpace News Archive

Waters Corporation announced its financial results for the first quarter of 2023.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, released a new report on lupus, a chronic autoimmune disease that can in some severe cases lead to permanent tissue damage, and may affect the skin, joints, heart, lungs, kidneys, circulating blood cells, or brain.

Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, announced it will participate in a fireside chat at the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day in New York City on Monday, May 15, 2023.

HOOKIPA Pharma Inc. announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400, an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead.

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, will sponsor a Women in Surgery Dinner on May 10, 2023, at the International Hernia Collaboration Conference in Rio de Janeiro, Brazil.

ALX Oncology Holdings Inc. announced the initiation of a Phase 2 investigator-sponsored trial of evorpacept, a next generation CD47 blocker, in combination with liposomal doxorubicin and KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with recurrent platinum-resistant ovarian cancer at the UPMC Hillman Cancer Center.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the first quarter ended March 31, 2023.

Acumen Pharmaceuticals, Inc. reported financial results for the first quarter of 2023 and provided a business update.

Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

Trevena, Inc. announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023.